Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study

Frontline therapy of multiple myeloma

(2015) P. Moreau et al.   BLOOD

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

(2015) M. Merz et al.   HAEMATOLOGICA

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

(2015) M. Merz et al.   HAEMATOLOGICA

Subcutaneous Versus Intravenous Bortezomib

(2014) Meagan S. Barbee et al.   ANNALS OF PHARMACOTHERAPY

Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma

(2014) A. Lok et al.   HAEMATOLOGICA

Current treatment landscape for relapsed and/or refractory multiple myeloma

(2014) Meletios A. Dimopoulos et al.   Nature Reviews Clinical Oncology

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY